This infographic compares the price of a selection of pharmaceutical drugs in the U.S. and abroad as of Jan. 2026 (in U.S. dollars).

Hanmi Pharmaceutical signed an agreement last Tuesday with Boehringer Ingelheim Korea to distribute and promote three chronic obstructive pulmonary disease (COPD) treatments nationwide: Spiriva ...

Boehringer Ingelheim today announced the launch of its new direct-to-consumer platform, “Boehringer Ingelheim Access.” The platform will offer a convenient way for patients in the U.S. to order and ...

Stiolto Respimat (tiotropium bromide/olodaterol) is an inhaled medication for the treatment of chronic obstructive pulmonary disease (COPD), bronchitis, and emphysema. However, it is not indicated for ...

Objectives This post hoc analysis of TIOtropium Safety and Performance In Respimat (TIOSPIR) evaluated safety and exacerbation efficacy in patients with stable (≥2 months) use of tiotropium HandiHaler ...

When I read the news that three out of four manufacturers of asthma and COPD inhalers have decided to cap the price to the patient to no more than $35 a month, it came as a shockingly pleasant ...

As we recently discussed, the Federal Trade Commission (“FTC”) sent warning letters to certain drug manufacturers regarding their purportedly improper listing of device patents in the Food and Drug ...

One of the top inhaler manufacturers in the U.S. announced plans on Thursday to cap the out-of-pocket cost of all its inhalers at $35 a month starting later this year after facing Democratic ire.

DEAR DR. ROACH: I am a 73-year-old male with chronic obstructive pulmonary disease (COPD). I pretty much have it under control with medication, but I am still not able to do a whole lot, as I feel ...

Min Son of Hanol IP & Law looks ahead at the key deadlines in the South Korean drug patent market for 2021 With each new year, pharmaceutical companies are faced with the loss of exclusivity that ...